Is TCV-116 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use TCV-116? Is TCV-116 safe for nursing mother and child? Does TCV-116 extracts into breast milk? Does TCV-116 has any long term or short term side effects on infants? Can TCV-116 influence milk supply or can TCV-116 decrease milk supply in lactating mothers?
TCV-116 lactation summary
- DrLact safety Score for TCV-116 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of TCV-116 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that TCV-116 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of TCV-116 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using TCV-116 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About TCV-116 usage in lactation
At latest update, relevant published data on excretion into breast milk were not found. A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption. Case report of kidney function impairment of a baby whose mother had taken Telmisartan in pregnancy. Until more data on this medication is available, safer alternative drugs are preferred, especially in premature babies or during the neonatal period. Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan
Alternate Drugs for Anti-hypertensive Angiotensin II receptor antagonists. ATC C09C
Eprosartan(Low Risk)
Irbesartan(Unsafe)
Losartan(Low Risk)
Telmisartan(Unsafe)
Valsartan(Low Risk)
Aliskiren(Low Risk)
Candesartan Cilexetil(Low Risk)
Losartan Potassium(Low Risk)
Olmesartan Medoxomil(Low Risk)
CS-866(Low Risk)